InvestorsHub Logo
Followers 19
Posts 2315
Boards Moderated 0
Alias Born 03/12/2013

Re: dcspka post# 25872

Wednesday, 10/29/2014 12:51:32 PM

Wednesday, October 29, 2014 12:51:32 PM

Post# of 30046
DC We will post what the skeptic stated about ADI being a wholly subsidiary of Radient..As you will see, the agreement was June 6m 2013, showing ADI as a Wholly owned subsidiary then 5 days later,ADI became a division..As you and we know..Radient can change a Wholly owned subsidiary to division at a"whim"..Proof shows that we are a Division from the 8-K..

http://www.sec.gov/Archives/edgar/data/838879/000121390013003193/f8k061113a1ex10i_radient.htm

This License Agreement (the “Agreement”), which shall be effective as of June 6th , 2013, is by and between Uni Pharma Co., Ltd., a Taipei, Taiwan limited liability company (“UNI”) and Radient Pharmaceuticals Corporation (including its subsidiary AMDL Diagnostics Inc.) a Delaware incorporated United States company (“RXPC”).

The 8=K was dated June 18, 2013...

Section 1 - Registrant’s Business and Operations

Item 1.01 - Entry into Material Definitive Agreements

We filed a Current Report on Form 8-K on June 11, 2013 to disclose our entry into a 5-year license agreement between AMDL Diagnostics, Inc. (“ADI”), a division within our company, and Uni Pharma Co., Ltd. a Taipei Taiwan limited liability company (“UNI”) that provides UNI with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure® (formerly called DR-70 cancer blood test kits (the “Tests”), procedures, analyses, data, know how, manufacturing, manufacturing processes, components, trademarks and intellectual property.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.